Quantitation of virus-specific classes of antibodies following immunization of mice with attenuated equine herpesvirus 1 and viral glycoprotein D.

The antibody responses of CBA/J mice infected intranasally (i.n.) with either the attenuated KyA strain or the pathogenic RacL11 strain of equine herpesvirus 1 (EHV-1) or immunized with recombinant glycoprotein D (rgD) were investigated using the ELISPOT assay to measure EHV-1-specific antibody-secreting cells (ASC) in the regional lymphoid tissue of the respiratory tract. IgG, IgA, and IgM ASC specific for EHV-1 were detected in the mediastinal lymph nodes (MLN) and lungs 2 weeks after i.n. infection with EHV-1 strain KyA or RacL11, or immunization with heat-killed KyA or rgD. EHV-1-specific ASC were present in the MLN and lungs at 4 and 8 weeks, but declined in frequency by fivefold in the lung at 8 weeks. However, i.n. immunized (2 x 10(6) pfu KyA or 50 microgram rgD/mouse) mice infected at 8 weeks with pathogenic EHV-1 RacL11 resisted challenge and showed eight- and tenfold increases in MLN ASC and lung ASC, respectively, by 3 days after challenge. In contrast to the intranasal route of immunization, intraperitoneal immunization yielded ASC frequencies in the MLN and lungs that were only slightly above those of nonimmunized control mice. These data indicate that immunization with infectious or heat-killed EHV-1 KyA, or rgD, induces significant levels of virus-specific ASC both in the MLN and lungs, a specific memory B-cell response, and long-term protective immunity. The finding that the numbers of ASC induced by the pathogenic strain versus the attenuated strain of EHV-1, which were virtually identical, indicated that the ability to generate a B-cell response is independent of and does not contribute to EHV-1 virulence.

[1]  H. Drummer,et al.  Epidemiological studies of equine herpesvirus 1 (EHV-1) in Thoroughbred foals: a review of studies conducted in the Hunter Valley of New South Wales between 1995 and 1997. , 1999, Veterinary microbiology.

[2]  D. Love,et al.  DNA-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection. , 1999, Vaccine.

[3]  R. Webster,et al.  Encyclopedia of virology , 1999 .

[4]  N. Osterrieder,et al.  Protective immunity against equine herpesvirus type-1 (EHV-1) infection in mice induced by recombinant EHV-1 gD. , 1998, Virus research.

[5]  Patrick M. Smith,et al.  Characterization of the Cytolytic T-Lymphocyte Response to a Candidate Vaccine Strain of Equine Herpesvirus 1 in CBA Mice , 1998, Journal of Virology.

[6]  J. Gilkerson,et al.  Immune responses and protective efficacy of recombinant baculovirus-expressed glycoproteins of equine herpesvirus 1 (EHV-1) gB, gC and gD alone or in combinations in BALB/c mice. , 1998, Veterinary microbiology.

[7]  T. Matsumura,et al.  An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses. , 1998, Virology.

[8]  N. Osterrieder,et al.  Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection. , 1997, Virology.

[9]  R. A. Killington,et al.  High level expression of equine herpesvirus 1 glycoproteins D and H and their role in protection against virus challenge in the C3H (H-2Kk) murine model. , 1997, Virus research.

[10]  B. Fakler,et al.  Synthesis and processing of the equine herpesvirus 1 glycoprotein M. , 1997, Virology.

[11]  J. Eldridge,et al.  Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization , 1997, Infection and immunity.

[12]  M. Lamm Interaction of antigens and antibodies at mucosal surfaces. , 1997, Annual review of microbiology.

[13]  N. Osterrieder,et al.  The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence. , 1996, Virology.

[14]  R. A. Killington,et al.  The production of a truncated form of baculovirus expressed EHV-1 glycoprotein C and its role in protection of C3H (H-2Kk) mice against virus challenge. , 1996, Virus research.

[15]  S. Jennings,et al.  Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers in mice challenged with a pathogenic strain, RacL. , 1996, Virus research.

[16]  H. Greenberg,et al.  Protective Effect of Rotavirus VP6-Specific IgA Monoclonal Antibodies That Lack Neutralizing Activity , 1996, Science.

[17]  N. Osterrieder,et al.  The equine herpesvirus 1 IR6 protein is nonessential for virus growth in vitro and modified by serial virus passage in cell culture. , 1996, Virology.

[18]  A. Sjölander,et al.  Kinetics, Localization and Isotype Profile of Antibody Responses to Immune Stimulating Complexes (Iscoms) Containing Human Influenza Virus Envelope Glycoproteins , 1996, Scandinavian journal of immunology.

[19]  H. Arvilommi ELISPOT for detecting antibody‐secreting cells in response to infections and vaccination , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[20]  R. A. Killington,et al.  The expression of the proteins of equine herpesvirus 1 which share homology with herpes simplex virus 1 glycoproteins H and L. , 1996, Virus research.

[21]  R. A. Killington,et al.  Role of T-cells, virus neutralising antibodies and complement-mediated antibody lysis in the immune response against equine herpesvirus type-1 (EHV-1) infection of C3H (H-2k) and BALB/c (H-2d) mice. , 1995, Research in veterinary science.

[22]  M. Sangster,et al.  Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection. , 1995, Virology.

[23]  E. Janoff,et al.  Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. , 1995, The Journal of infectious diseases.

[24]  R. Wagner,et al.  Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). , 1995, Virology.

[25]  D. Haines,et al.  Cellular and antibody responses to equine herpesviruses 1 and 4 following vaccination of horses with modified-live and inactivated viruses. , 1995, Journal of the American Veterinary Medical Association.

[26]  R. Chervenak,et al.  In utero exposure to ethanol affects postnatal development of T- and B-lymphocytes, but not natural killer cells. , 1995, Alcoholism, clinical and experimental research.

[27]  D. Bernstein,et al.  Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. , 1995, Virology.

[28]  H. Suomalainen,et al.  Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. , 1995, Vaccine.

[29]  B. Murphy,et al.  Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. , 1995, Vaccine.

[30]  R. Wagner,et al.  Expression of equine herpesvirus type 1 glycoprotein gp14 in Escherichia coli and in insect cells: a comparative study on protein processing and humoral immune responses. , 1994, The Journal of general virology.

[31]  D. Love,et al.  Characterization of immune responses to baculovirus-expressed equine herpesvirus type 1 glycoproteins D and H in a murine model. , 1994, The Journal of general virology.

[32]  D. Klinman,et al.  Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein. , 1994, Journal of acquired immune deficiency syndromes.

[33]  K. Mostov Transepithelial transport of immunoglobulins. , 1994, Annual review of immunology.

[34]  D. Boyle,et al.  Expression of equine herpesvirus 1 glycoprotein D by using a recombinant baculovirus , 1993, Journal of virology.

[35]  R. F. Cook,et al.  Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain. , 1993, Research in veterinary science.

[36]  C. Chougnet,et al.  Quantification of antibody‐secreting lymphocytes that react with Pf155/RESA from Plasmodium falciparum: an ELISPOT assay for field studies , 1993, Clinical and Experimental Immunology.

[37]  M. Russell,et al.  Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit , 1993, Infection and immunity.

[38]  G. Lüchters,et al.  Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. , 1993, Vaccine.

[39]  C. Kaetzel,et al.  Intracellular neutralization of virus by immunoglobulin A antibodies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Levine,et al.  Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. , 1992, The Journal of clinical investigation.

[41]  C. Wennerås,et al.  Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine , 1992, Infection and immunity.

[42]  N. Dimmock,et al.  Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited , 1992, Journal of virology.

[43]  C. Czerkinsky,et al.  Mucosal immunity: implications for vaccine development. , 1992, Immunobiology.

[44]  A. Awan,et al.  A murine model for studying EHV-1-induced abortion. , 1991, Research in veterinary science.

[45]  J. Biewenga,et al.  Mucosal and systemic antibody formation in the rat after intranasal administration of three different antigens , 1991, Immunology and cell biology.

[46]  D. Onions Equine herpesvirus: new approaches to an old problem. , 1991, Equine veterinary journal.

[47]  M. Levine,et al.  Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. , 1990, Vaccine.

[48]  S. Goebel,et al.  Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity , 1990, Journal of virology.

[49]  A. Awan,et al.  The pathogenesis of equine herpesvirus type 1 in the mouse: a new model for studying host responses to the infection. , 1990, The Journal of general virology.

[50]  N. Nowotny,et al.  Viraemia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses. , 1990, The Veterinary quarterly.

[51]  S. Goebel,et al.  Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals , 1989, Journal of virology.

[52]  G. Allen,et al.  A hamster model of equine herpesvirus type 1 (EHV-1) infection; passive protection by monoclonal antibodies to EHV-1 glycoproteins 13, 14 and 17/18. , 1989, The Journal of general virology.

[53]  R. Stead,et al.  Novel cellular interactions and networks involving the intestinal immune system and its microenvironment , 1989, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[54]  C. Czerkinsky,et al.  A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. , 1988, Journal of immunological methods.

[55]  R. Belshe,et al.  Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines , 1988, Journal of clinical microbiology.

[56]  Bryans Jt,et al.  Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. , 1986 .

[57]  B. Murphy,et al.  Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans , 1985, Journal of clinical microbiology.

[58]  J. Bienenstock Immunology of the lung and upper respiratory tract , 1984 .

[59]  O Ouchterlony,et al.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.

[60]  P. Holt,et al.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.

[61]  L. Coggins,et al.  Response of pregnant mares to equine herpesvirus 1 (EHV1). , 1980, The Cornell veterinarian.

[62]  K. Mcintosh,et al.  Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection , 1979, Infection and immunity.

[63]  D. O’Callaghan,et al.  Studies of the molecular anatomy of the L-M cell strain of equine herpes virus type 1: proteins of the nucleocapsid and intact virion. , 1974, Virology.